9 results on '"Branco de Barros AL"'
Search Results
2. Nuclear factor kappa B expression in non-small cell lung cancer.
- Author
-
Zhang L, Ludden CM, Cullen AJ, Tew KD, Branco de Barros AL, and Townsend DM
- Subjects
- Humans, NF-kappa B metabolism, Gene Expression Regulation, Protein Processing, Post-Translational, Carcinoma, Non-Small-Cell Lung pathology, Lung Neoplasms pathology
- Abstract
In this mini-review, we discuss the role of NF-κB, a proinflammatory transcription factor, in the expression of genes involved in inflammation, proliferation, and apoptosis pathways, and link it with prognosis of various human cancers, particularly non-small cell lung cancer (NSCLC). We and others have shown that NF-κB activity can be impacted by post-translational S-glutathionylation through reversible formation of a mixed disulfide bond between its cysteine residues and glutathione (GSH). Clinical data analysis showed that high expression of NF-κB correlated with shorter overall survival (OS) in NSCLC patients, suggesting a tumor promotion function for NF-κB. Moreover, NF-κB expression was associated with tumor stage, lymph node metastasis, and 5-year OS in these patients. NF-κB was over-expressed in the cytoplasm of tumor tissue compared to adjacent normal tissues. S-glutathionylation of NF-κB caused negative regulation by interfering with DNA binding activities of NF-κB subunits. In response to oxidants, S-glutathionylation of NF-κB also correlated with enhanced lung inflammation. Thus, S-glutathionylation is an important contributor to NF-κB regulation and clinical results highlight the importance of NF-κB in NSCLC, where NF-κB levels are associated with unfavorable prognosis., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Danyelle M. Townsend reports financial support was provided by Medical University of South Carolina. DMT and ADB serve as Editors for Biomedicine and Pharmacotherapy., (Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
3. Alpha-tocopheryl succinate and doxorubicin-loaded liposomes improve drug uptake and tumor accumulation in a murine breast tumor model.
- Author
-
Boratto FA, Lages EB, Loures CMC, Sabino AP, Malachias A, Townsend DM, Branco De Barros AL, Miranda Ferreira LA, and Amaral Leite E
- Subjects
- Mice, Animals, Humans, Female, Cell Line, Tumor, Doxorubicin pharmacology, alpha-Tocopherol pharmacology, Succinates, Liposomes, Breast Neoplasms drug therapy
- Abstract
Liposomes composed of a rigid bilayer have high plasma stability; however, they can be challenged in efficacy due to complications in releasing the encapsulated drug as well as being internalized by the tumor cell. On the other hand, fusogenic liposomes may fuse with the plasmatic membrane and release encapsulated material directly into the cytoplasm. In a previous study, fusogenic liposomes composed of alpha-tocopheryl succinate (TS) and doxorubicin (DOX) were developed (pHSL-TS-DOX). These stabilized tumor growth and reduced toxicity compared to a commercial formulation. In the present study, we investigated whether cellular uptake or DOX accumulation in the tumor could justify the better performance of the pHSL-TS-DOX formulation. Release, deformability, and DOX plasmatic concentration studies were also carried out. pHSL-TS-DOX showed an adequate release profile and demonstrated characteristics of a deformable formulation. Data from apoptosis, cell cycle, and nuclear morphology studies have shown that the induction of cell death caused by pHSL-TS-DOX occurred more quickly. Higher DOX cellular uptake and tumor accumulation were observed when pHSL-TS-DOX was administered, demonstrating better drug delivery capacity. Therefore, better DOX uptake as well as tumor accumulation explain the great antitumor activity previously demonstrated for this formulation., Competing Interests: Declaration of Competing Interest The authors, above cited, declare that there is no conflict of interest., (Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
4. Recent advances in point of care testing for COVID-19 detection.
- Author
-
Fernandes RS, de Oliveira Silva J, Gomes KB, Azevedo RB, Townsend DM, de Paula Sabino A, and Branco de Barros AL
- Subjects
- COVID-19 Testing, Clinical Laboratory Techniques methods, Humans, Molecular Diagnostic Techniques methods, Pandemics, Point-of-Care Testing, RNA, Viral, SARS-CoV-2 genetics, Sensitivity and Specificity, COVID-19 diagnosis
- Abstract
The World Health Organizations declaration of the COVID-19 pandemic was a milestone for the scientific community. The high transmission rate and the huge number of deaths, along with the lack of knowledge about the virus and the evolution of the disease, stimulated a relentless search for diagnostic tests, treatments, and vaccines. The main challenges were the differential diagnosis of COVID-19 and the development of specific, rapid, and sensitive tests that could reach all people. RT-PCR remains the gold standard for diagnosing COVID-19. However, new methods, such as other molecular techniques and immunoassays emerged. Also, the need for accessible tests with quick results boosted the development of point of care tests (POCT) that are fast, and automated, with high precision and accuracy. This assay reduces the dependence on laboratory conditions and mass testing of the population, dispersing the pressure regarding screening and detection. This review summarizes the advances in the diagnostic field since the pandemic started, emphasizing various laboratory techniques for detecting COVID-19. We reviewed the main existing diagnostic methods, as well as POCT under development, starting with RT-PCR detection, but also exploring other nucleic acid techniques, such as digital PCR, loop-mediated isothermal amplification-based assay (RT-LAMP), clustered regularly interspaced short palindromic repeats (CRISPR), and next-generation sequencing (NGS), and immunoassay tests, and nanoparticle-based biosensors, developed as portable instruments for the rapid standard diagnosis of COVID-19., Competing Interests: Conflict of interest statement The authors declare that they have no conflict of interest., (Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
5. pH-sensitive doxorubicin-tocopherol succinate prodrug encapsulated in docosahexaenoic acid-based nanostructured lipid carriers: An effective strategy to improve pharmacokinetics and reduce toxic effects.
- Author
-
Lages EB, Fernandes RS, Andrade MMS, Paiyabhroma N, de Oliveira RB, Fernandes C, Cassali GD, Sicard P, Richard S, Branco de Barros AL, and Ferreira LAM
- Subjects
- Animals, Antibiotics, Antineoplastic administration & dosage, Antibiotics, Antineoplastic adverse effects, Breast Neoplasms drug therapy, Cell Line, Tumor, Doxorubicin administration & dosage, Doxorubicin adverse effects, Drug Carriers, Drug Compounding, Drug Liberation, Humans, Hydrazones chemistry, Hydrogen-Ion Concentration, Lipids chemistry, Long QT Syndrome chemically induced, Mice, Mice, Inbred BALB C, Nanostructures, Neoplasm Transplantation, Ventricular Function, Left drug effects, Antibiotics, Antineoplastic pharmacokinetics, Docosahexaenoic Acids chemistry, Doxorubicin pharmacokinetics, Prodrugs, alpha-Tocopherol chemistry
- Abstract
Side effects often limit the use of doxorubicin (DOX) in cancer treatment. We have recently developed a nanostructured lipid carrier (NLC) formulation for synergistic chemotherapy, encapsulating DOX and the anticancer adjuvants docosahexaenoic acid (DHA) and α-tocopherol succinate (TS). Hydrophobic ion-pairing with TS allowed a high DOX entrapment in the nanocarrier. In this work, we investigated the pharmacokinetics of this formulation after intravenous administration in mice. The first data obtained led us to propose synthesizing covalent DOX-TS conjugates to increase DOX retention in the NLC. We successfully conjugated DOX to TS via an amide or hydrazone bond. In vitro studies in 4T1 tumor cells indicated low cytotoxicity of the amide derivative, while the hydrazone conjugate was effective in killing cancer cells. We encapsulated the hydrazone derivative in a DHA-based nanocarrier (DOX-hyd-TS/NLC), which had reduced particle size and high drug encapsulation efficiency. The pH-sensitive hydrazone bond allowed controlled DOX release from the NLC, with increased drug release at acidic conditions. In vivo studies revealed that DOX-hyd-TS/NLC had a better pharmacokinetic profile than free DOX and attenuated the short-term cardiotoxic effects caused by DOX, such as QT prolongation and impaired left ventricular systolic function. Moreover, this formulation showed excellent therapeutic performance by reducing tumor growth in 4T1 tumor-bearing mice and decreasing DOX-induced toxicity to the heart and liver, demonstrated by hematologic, biochemical, and histologic analyses. These results indicate that DOX-hyd-TS/NLC may be a promising nanocarrier for breast cancer treatment., (Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
6. pH-responsive and folate-coated liposomes encapsulating irinotecan as an alternative to improve efficacy of colorectal cancer treatment.
- Author
-
Nunes SS, Miranda SEM, de Oliveira Silva J, Fernandes RS, de Alcântara Lemos J, de Aguiar Ferreira C, Townsend DM, Cassali GD, Oliveira MC, and Branco de Barros AL
- Subjects
- Animals, Cell Line, Tumor, Colorectal Neoplasms metabolism, Colorectal Neoplasms pathology, Delayed-Action Preparations, Drug Compounding, Drug Liberation, Folic Acid chemistry, Hydrogen-Ion Concentration, Irinotecan chemistry, Irinotecan metabolism, Liposomes, Mice, Inbred BALB C, Necrosis, Time Factors, Topoisomerase I Inhibitors chemistry, Topoisomerase I Inhibitors metabolism, Tumor Burden drug effects, Mice, Colorectal Neoplasms drug therapy, Folic Acid metabolism, Irinotecan administration & dosage, Lipids chemistry, Topoisomerase I Inhibitors administration & dosage
- Abstract
Irinotecan (IRN) is a semisynthetic derivative of camptothecin that acts as a topoisomerase I inhibitor. IRN is used worldwide for the treatment of several types of cancer, including colorectal cancer, however its use can lead to serious adverse effects, as diarrhea and myelosuppression. Liposomes are widely used as drug delivery systems that can improve chemotherapeutic activity and decrease side effects. Liposomes can also be pH-sensitive to release its content preferentially in acidic environments, like tumors, and be surface-functionalized for targeting purposes. Herein, we developed a folate-coated pH-sensitive liposome as a drug delivery system for IRN to reach improved tumor therapy without potential adverse events. Liposomes were prepared containing IRN and characterized for particle size, polydispersity index, zeta potential, concentration, encapsulation, cellular uptake, and release profile. Antitumor activity was investigated in a murine model of colorectal cancer, and its toxicity was evaluated by hematological/biochemical tests and histological analysis of main organs. The results showed vesicles smaller than 200 nm with little dispersion, a surface charge close to neutral, and high encapsulation rate of over 90%. The system demonstrated prolonged and sustained release in pH-dependent manner with high intracellular drug delivery capacity. Importantly, the folate-coated pH-sensitive formulation had significantly better antitumor activity than the pH-dependent system only or the free drug. Tumor tissue of IRN-containing groups presented large areas of necrosis. Furthermore, no evidence of systemic toxicity was found for the groups investigated. Thus, our developed nanodrug IRN delivery system can potentially be an alternative to conventional colorectal cancer treatment., (Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
7. Thermosensitive Nanosystems Associated with Hyperthermia for Cancer Treatment.
- Author
-
Pereira Gomes I, Aparecida Duarte J, Chaves Maia AL, Rubello D, Townsend DM, Branco de Barros AL, and Leite EA
- Abstract
Conventional chemotherapy regimens have limitations due to serious adverse effects. Targeted drug delivery systems to reduce systemic toxicity are a powerful drug development platform. Encapsulation of antitumor drug(s) in thermosensitive nanocarriers is an emerging approach with a promise to improve uptake and increase therapeutic efficacy, as they can be activated by hyperthermia selectively at the tumor site. In this review, we focus on thermosensitive nanosystems associated with hyperthermia for the treatment of cancer, in preclinical and clinical use.
- Published
- 2019
- Full Text
- View/download PDF
8. Technetium-99m-labeled lapachol as an imaging probe for breast tumor identification.
- Author
-
Miranda SE, Lemos JA, Fernandes RS, Ottoni FM, Alves RJ, Ferretti A, Rubello D, Cardoso VN, and Branco de Barros AL
- Subjects
- Animals, Breast Neoplasms metabolism, Female, Mice, Mice, Inbred BALB C, Tissue Distribution, Breast Neoplasms diagnostic imaging, Naphthoquinones pharmacokinetics, Technetium pharmacokinetics
- Abstract
Objective: Breast cancer is a health problem worldwide with high incidence and mortality rates. It is well known that the development of more sensitive and specific diagnostic methods is of great importance since an early diagnosis is essential to successfully treat tumors. Lapachol is a natural compound, belonging to the naphthoquinone group that has been widely used in traditional medicine to treat various illnesses, including cancer. The aim of this study was to evaluate technetium-99m (
99m Tc) labeled lapachol as an imaging probe for breast cancer identification., Methods: To achieve this purpose, lapachol was labeled with99m Tc, radiochemical purity and in vitro stability were determined. Blood clearance, in healthy mice, and biodistribution, in 4T1 tumor-bearing mice, were also evaluated., Results: Lapachol was successfully labeled with99m Tc, with high values of radiochemical yield (95.9±3.4%). In vitro stability showed that the radiolabeled complex remained stable for up to 24h, with values above 90% for both saline and plasma (95.6±3.6% and 96.4±1.7%, respectively). The radiolabeled complex decays in a biphasic manner, with a half-life of distribution and elimination equal to 3.3 and 50.0min, respectively. Biodistribution and scintigraphic images showed high uptake in organs of excretion (kidneys, liver, and intestine). It could be also noted that tumor uptake was higher than the muscle at all time points. Tumor-to-muscle ratio reaches ∼4.5 at 24h after administration., Conclusion: These findings suggest that99m Tc-lapachol can be a potential diagnostic agent for breast tumors., (Copyright © 2019 Sociedad Española de Medicina Nuclear e Imagen Molecular. Publicado por Elsevier España, S.L.U. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
9. Identification of Staphylococcus aureus infection by aptamers directly radiolabeled with technetium-99m.
- Author
-
dos Santos SR, Rodrigues Corrêa C, Branco de Barros AL, Serakides R, Fernandes SO, Cardoso VN, and de Andrade AS
- Subjects
- Animals, Candida albicans physiology, Candidiasis diagnostic imaging, Cysteine chemistry, Drug Stability, Isotope Labeling, Mice, Radionuclide Imaging, Tissue Distribution, Aptamers, Nucleotide chemistry, Aptamers, Nucleotide pharmacokinetics, Staphylococcal Infections diagnostic imaging, Staphylococcus aureus physiology, Technetium
- Abstract
Introduction: Aptamers are oligonucleotides that have high affinity and specificity for their molecular targets which are emerging as a new class of molecules for radiopharmaceuticals development. In this study, aptamers selected to Staphylococcus aureus were evaluated for bacterial infection identification., Methods: Anti S. aureus aptamers were labeled with (99m)Tc by the direct method. The radiolabel yield and complex stability were assessed by thin-layer chromatography (TLC). Three groups of Swiss mice containing 6 animals each were used. The first group was infected intramuscularly in the right thigh with S. aureus. The second group was infected in the same way with C. albicans and the third group was injected with zymosan to induce aseptic inflammation. After 24 h, radiolabeled aptamers (22.2 MBq) were injected by the tail vein. The mice were euthanized 4 h post injection and tissue sample activities measured in a gamma counter., Results: The (99m)Tc labeled aptamers were stable in saline, plasma and cystein excess. Radiolabeled aptamers showed increased uptake in the kidneys for all groups indicating a main renal excretion, which is consistent with the hydrophilic nature and small size of aptamers. The radiopharmaceutical showed rapid blood clearance indicated by a reduced dose (% ID/g) in the blood. The biodistribution showed that aptamers were able to identify the infection foci caused by S. aureus displaying a target/non-target ratio of 4.0±0.5. This ratio for mice infected with C. albicans was 2.0±0.4 while for mice with aseptic inflammation was 1.2±0.2. Histology confirmed the presence of infection in groups 1 and 2, and inflammation in group 3., Conclusions: The biodistibution study demonstrated a statistically higher uptake in the S. aureus foci relative to inflammation and C. albicans infected areas. These results highlight the potential of aptamers labeled directly with (99m)Tc for bacterial infection diagnosis by scintigraphy., (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.